We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

QuidelOrtho

Develops, manufactures and markets rapid diagnostic tests that focus on infectious diseases, reproductive health, and... read more Featured Products: More products

Download Mobile App




YKL-40 Associated with Severity in Patients with Necrotizing Soft-Tissue Infection

By LabMedica International staff writers
Posted on 28 Oct 2021
Necrotizing soft-tissue infection (NSTI) is a rare, severe and fast-progressing bacterial infection. More...
NSTI can be caused by a myriad of aerobic, anaerobic and facultative anaerobic bacteria, but predominantly by Group A Streptococcus in monomicrobial infections.

YKL-40, also called chitinase-3-like-1 protein, may be an attractive prognostic biomarker in NSTI. YKL-40 is an acute phase protein secreted by several of immune cells, including macrophages, neutrophils and endothelial cells. Proteomic analysis has indicated YKL-40 as a promising biomarker in patients with severe sepsis and septic shock.

Clinical Scientists at the Copenhagen University Hospital (Copenhagen, Denmark) investigated the association between plasma YKL-40 and 30-day mortality in patients with NSTI, and assessed its value as a marker of disease severity. They determined plasma YKL-40 levels in 161 patients with NSTI and 65 age-sex matched controls upon admission and at day 1, 2 and 3.

Patient had blood samples collected into ethylenediaminetetraacetic acid (EDTA) sample tubes upon admission (baseline), and at the following three days (all between 8 AM and 12 AM). Plasma YKL-40 was quantified in duplicates by commercial enzyme-linked immunosorbent (ELISA) technique (Quidel, San Diego, CA, USA) at each of the four time points. The minimal detectable limit for YKL-40 was 10 ng/mL.

The investigators reported that baseline plasma YKL-40 was 1,191 ng/mL in patients with NSTI compared with 40 ng/mL in controls. YKL-40 was found to be significantly higher in patients with septic shock (1,942 versus 720 ng/mL), and in patients receiving renal-replacement therapy (2,382 versus 1,041 ng/mL). YKL-40 correlated with Simplified Acute Physiology Score II. Baseline YKL-40 above 1,840 ng/mL was associated with increased risk of 30-day mortality in age-sex-comorbidity adjusted analysis (OR 3.77), but after further adjustment for Simplified Acute Physiology Score II no association was found between YKL-40 and early mortality.

Plasma YKL-40 was significantly higher in patients with NSTI compared to controls at admission, and at day 1 and 2. Plasma YKL-40 at admission was significantly higher among 45 patients infected with mono or polymicrobial Group A Streptococcus in blood and/or tissue (2,338 ng/mL) compared to 104 other types of NSTI (1,246 ng/mL). However, this was not observed at day 1, 2 and 3. No microbial findings were observed in 12 patients.

The authors concluded that high plasma YKL-40 levels were associated with disease severity and risk of death in patients with NSTI. However, YKL-40 is not an independent predictor for 30-day mortality. The study was published on October 9, 2021 in the journal BMC Infectious Diseases.

Related Links:
Copenhagen University Hospital
Quidel




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.